Revolutionizing Uterine Fibroid Care: Modern Minimally Invasive Treatments
Event Type
Research Presentation
Academic Department
Physics
Location
Dana Science Building, 2nd floor
Start Date
26-4-2024 1:30 PM
End Date
26-4-2024 3:00 PM
Description
Under the direction of Dr. Brian Gentry
Uterine fibroids are the most common benign tumors that grow in the muscle tissue of the uterus. There are seven types of fibroids, with three major ones, categorized by where they form: intramural (within the wall), submucosal (in the uterine cavity), and sub serosal (outside the uterus). The Dual Wavelength Diode Laser System (DWLS) and transcervical radiofrequency ablation (TRA) demonstrate recent advancements made in uterine treatment technology. DWLS reduces the size of fibroids with better results than prior laser treatments like CO2 and Nd-YAG lasers. An ex-vivo study evaluating DWLS achieved a substantial 46.6% reduction in fibroid volume across all types (D’Alterio et al., 2021). TRA utilizes radiofrequency energy to safely shrink myomas. Findings from SAGE, a registry focused on the long-term effects of TRA, demonstrated favorable outcomes from 160 women in the preliminary results. These minimally invasive approaches offer a compelling alternative to more invasive procedures due to their enhanced safety, precision, and shorter recovery times, signifying notable progress in uterine fibroid treatment.
Revolutionizing Uterine Fibroid Care: Modern Minimally Invasive Treatments
Dana Science Building, 2nd floor
Under the direction of Dr. Brian Gentry
Uterine fibroids are the most common benign tumors that grow in the muscle tissue of the uterus. There are seven types of fibroids, with three major ones, categorized by where they form: intramural (within the wall), submucosal (in the uterine cavity), and sub serosal (outside the uterus). The Dual Wavelength Diode Laser System (DWLS) and transcervical radiofrequency ablation (TRA) demonstrate recent advancements made in uterine treatment technology. DWLS reduces the size of fibroids with better results than prior laser treatments like CO2 and Nd-YAG lasers. An ex-vivo study evaluating DWLS achieved a substantial 46.6% reduction in fibroid volume across all types (D’Alterio et al., 2021). TRA utilizes radiofrequency energy to safely shrink myomas. Findings from SAGE, a registry focused on the long-term effects of TRA, demonstrated favorable outcomes from 160 women in the preliminary results. These minimally invasive approaches offer a compelling alternative to more invasive procedures due to their enhanced safety, precision, and shorter recovery times, signifying notable progress in uterine fibroid treatment.